Clearmind Medicine (XCNQ:CMND) EPS (Diluted) : C$-57.70 (TTM As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine EPS (Diluted)?

Clearmind Medicine's Earnings per Share (Diluted) for the three months ended in Oct. 2023 was C$-6.70. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-57.70.

Clearmind Medicine's EPS (Basic) for the three months ended in Oct. 2023 was C$-6.70. Its EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-57.70.

Clearmind Medicine's EPS without NRI for the three months ended in Oct. 2023 was C$-4.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2023 was C$-55.32.

During the past 3 years, the average EPS without NRIGrowth Rate was -40.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -48.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Clearmind Medicine's highest 3-Year average EPS without NRI Growth Rate was -40.30% per year. The lowest was -154.80% per year. And the median was -69.20% per year.

Clearmind Medicine EPS (Diluted) Historical Data

The historical data trend for Clearmind Medicine's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine EPS (Diluted) Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

EPS (Diluted)

Get a 7-Day Free Trial

-9.00

-22.80

-88.16

-159.11

-42.58

Clearmind Medicine Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
EPS (Diluted)	Get a 7-Day Free Trial															-34.31	-32.10	-16.50	-2.40	-6.70

Competitive Comparison of Clearmind Medicine's EPS (Diluted)

For the Biotechnology subindustry, Clearmind Medicine's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's PE Ratio distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's PE Ratio falls into.

Clearmind Medicine EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Clearmind Medicine's Diluted EPS for the fiscal year that ended in Oct. 2023 is calculated as

Diluted EPS (A: Oct. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.621	-	0)	/	0.202
	=	-42.68

Clearmind Medicine's Diluted EPS for the quarter that ended in Oct. 2023 is calculated as

Diluted EPS (Q: Oct. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-4.07	-	0)	/	0.607
	=	-6.71

EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-57.70

Clearmind Medicine (XCNQ:CMND) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clearmind Medicine EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (XCNQ:CMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

CMND:USA CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.